Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Atyr Pharma Inc. (ATYR) Insider Trading Activity
Healthcare • Biotechnology • 56 employees
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Total Value
$1,861.66
Total Shares
14,659
Average Trade Value
$372.33
Most Active Insider
Shukla Sanjay
Total Activity: $10,000
Largest Single Transaction
$10,000
by Shukla Sanjay on Feb 3, 2025
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Chief Financial Officer
|
Feb 4, 2025 | 1,254 | $4,740 | 31,763 (-3.9%) | Sale | |
|
General Counsel
|
Feb 4, 2025 | 899 | $3,398 | 26,555 (-3.4%) | Sale | |
|
Chief Financial Officer
|
Feb 3, 2025 | 3,750 | $0 | 33,017 (+11.4%) | Exercise/Conversion | |
|
General Counsel
|
Feb 3, 2025 | 2,687 | $0 | 27,454 (+9.8%) | Exercise/Conversion | |
|
President and CEO
|
Feb 3, 2025 | 10,375 | $10,000 | 146,923 (+7.1%) | Exercise/Conversion |